Findings

What do systematic reviews say?

4,776 questions · 7,311 findings · 959 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1,498 · 20.5%GRADE not reported 303 · 4.1%Very low 1,839 · 25.2%Low 1,991 · 27.2%Moderate 1,277 · 17.5%High 403 · 5.5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Low molecular weight heparin vs no thromboprophylaxis

Symptomatic VTE · ambulatory cancer patients receiving chemotherapy

Low‐molecular‐weight heparin leads to lower symptomatic VTE compared with no thromboprophylaxis (high certainty).

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 0.62 [0.46, 0.83]
11 studies · 3931 participants
High

Low molecular weight heparin vs no thromboprophylaxis

Major bleeding · ambulatory cancer patients receiving chemotherapy

Low‐molecular‐weight heparin probably leads to higher major bleeding compared with no thromboprophylaxis (moderate certainty).

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 1.63 [1.12, 2.35]
15 studies · 7282 participants
Moderate

First‐line low‐dose thiazide vs placebo

Total mortality · adults with primary hypertension

1 finding from 1 review

First‐line drugs for hypertension 2018 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 19874 participants
High

First‐line low‐dose thiazide vs placebo

Stroke · adults with primary hypertension

1 finding from 1 review

First‐line drugs for hypertension 2018 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 19874 participants
High

First‐line low‐dose thiazide vs placebo

Total coronary heart disease · adults with primary hypertension

1 finding from 1 review

First‐line drugs for hypertension 2018 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 19022 participants
High

First‐line low‐dose thiazide vs placebo

Cardiovascular events · adults with primary hypertension

1 finding from 1 review

First‐line drugs for hypertension 2018 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 19022 participants
High

First‐line low‐dose thiazide vs placebo

Withdrawals due to adverse events · adults with primary hypertension

1 finding from 1 review

First‐line drugs for hypertension 2018 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 8870 participants
Low

Summary of findings: low‐dose vs high‐dose PERT

Change in weight (kg) · adults and children with cystic fibrosis

1 finding from 1 review

Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 17 participants
Very low

Summary of findings: low‐dose vs high‐dose PERT

Change in height · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: low‐dose vs high‐dose PERT

Change in BMI · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: low‐dose vs high‐dose PERT

Frequency of bowel symptoms: stool frequency · adults and children with cystic fibrosis

1 finding from 1 review

Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 17 participants
Very low

Summary of findings: low‐dose vs high‐dose PERT

CFA: FFE (g/day) · adults and children with cystic fibrosis

1 finding from 1 review

Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 17 participants
Very low

Summary of findings: low‐dose vs high‐dose PERT

Adverse events · adults and children with cystic fibrosis

1 finding from 1 review

Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 146 participants
Very low

Summary of findings: low‐dose vs high‐dose PERT

Pulmonary exacerbations · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low‐dose adjuvant radiotherapy vs standard‐dose adjuvant radiotherapy

Overall survival · patients with HPV‐positive oropharyngeal carcinoma who have received minimally invasive transoral surgery

The review found no eligible studies for this question.

1 finding from 1 review

De‐intensified adjuvant (chemo)radiotherapy versus standard adjuvant chemoradiotherapy post transoral minimally… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low‐dose adjuvant radiotherapy vs standard‐dose adjuvant radiotherapy

Disease-free survival · patients with HPV‐positive oropharyngeal carcinoma who have received minimally invasive transoral surgery

The review found no eligible studies for this question.

1 finding from 1 review

De‐intensified adjuvant (chemo)radiotherapy versus standard adjuvant chemoradiotherapy post transoral minimally… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low‐dose adjuvant radiotherapy vs standard‐dose adjuvant radiotherapy

Voice (Voice Handicap Index) · patients with HPV‐positive oropharyngeal carcinoma who have received minimally invasive transoral surgery

The review found no eligible studies for this question.

1 finding from 1 review

De‐intensified adjuvant (chemo)radiotherapy versus standard adjuvant chemoradiotherapy post transoral minimally… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low‐dose mifepristone (< 25 mg) vs levonorgestrel 1.5 mg

Observed number of pregnancies (all women) · women seeking emergency contraception

Low‐dose mifepristone (< 25 mg) leads to lower observed number of pregnancies (all women) compared with levonorgestrel 1.5 mg (high certainty).

1 finding from 1 review

Interventions for emergency contraception 2019 · Cochrane Headline outcomes only
RR 0.72 [0.52, 0.99]
14 studies · 8752 participants
High

Low‐dose mifepristone (< 25 mg) vs levonorgestrel 1.5 mg

Side effects · women seeking emergency contraception

Low‐dose mifepristone (< 25 mg) may leads to lower any side effect compared with levonorgestrel 1.5 mg (low certainty).

1 finding from 1 review

Interventions for emergency contraception 2019 · Cochrane Headline outcomes only
RR 0.26 [0.17, 0.38]
3 studies · 609 participants
Low

Low‐dose mifepristone (< 25 mg) vs levonorgestrel 1.5 mg

Nausea · women seeking emergency contraception

Low‐dose mifepristone (< 25 mg) showed no clear difference in specific side effect ‐ nausea compared with levonorgestrel 1.5 mg (moderate certainty).

1 finding from 1 review

Interventions for emergency contraception 2019 · Cochrane Headline outcomes only
RR 0.95 [0.84, 1.09]
5 studies · 6384 participants
Moderate